N-Desethylisotonitazene
Clinical data | |
---|---|
Routes of administration | Oral, intransal, vaporized |
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
N-Desethylisotonitazene (norisotonitazene) is a benzimidazole opioid with potent analgesic effects which has been sold as a designer drug. It was first identified in 2023 as an active metabolite of the closely related compound isotonitazene, and was found to have similar potency. It is one of the strongest benzimidazole opioids discovered, with an analgesic strength 20 times stronger than fentanyl.
Starting in 2023, it has become an increasingly widespread drug of abuse in its own right, linked to numerous overdose cases, and may be considered an analog of the schedule 1 drug metonitazene. In October 2023, the DEA published an intent to temporarily schedule etonitazepipne and N-desethylisotonitazene. As of April 2024, it is not yet controlled in the United States.[1][2][3][4][5][6][7]
See also
References
- PMID 32091095.
- S2CID 232337929.
- PMID 34792157.
- S2CID 258880063.
- ^ Malcolm NJ, Palkovic B, Sprague DJ, Calkins MM, Lanham JK, Halberstadt AL, Stucke AG, McCorvy JD. Mu-opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression. ISCIENCE (2023)
- ^ Taylor M (30 January 2023). "Opioid 20x More Potent than Fentanyl Detected in Pennsylvania, Florida". Forensic.
- ^ "Federal Register :: Request Access".